Temuterkib (LY3214996, LY 3214996)是一种选择性、新型ERK1/2抑制剂，IC₅₀为5 nM，具有抗癌活性，并且已经进入临床实验。Temuterkib具有高效力和良好的溶解性，在具有突变型BRAF和RAS的癌细胞系中比其他ERK抑制剂拥有更好的抗癌活性。

参考文献

1.Shripad V. Bhagwat, et al. Abstract 4973: Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations. Cancer Research. July 2017.

2.Bhagwat SV, et al. ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine. Mol Cancer Ther. 2020 Feb;19(2):325-336.

冰袋运输。粉末直接保存于-20℃，有效期2年。建议分装后-20℃干燥保存，避免反复冻融。